---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-009227"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2025-01-27T23:59:59+00:00"
generated_at: "2026-05-27T09:53:36.747583+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lineage closes $6M second tranche of registered direct offering; total $30M received

## Summary
- Second tranche closed Jan 27, 2025; issued 7,894,737 common shares + warrants at $0.76/unit.
- Warrants exercisable at $0.91/share from May 21, 2025; expire on OpRegen Phase 2/3 milestone or May 2028.
- Potential additional $36M if all warrants exercised; $30M gross proceeds collected to date.
- Broadwood Partners (affiliate of board member Neal Bradsher) purchased the second tranche shares.
- Shareholders approved issuance at Jan 27 special meeting with 114.1M votes for, 6.7M against.

## SEC filing metadata
- accession: 0000950170-25-009227
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2025-01-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.07, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000095017025009227/0000950170-25-009227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000095017025009227/lctx-20250127.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-009227
- JSON: https://secwatch.observer/filing/0000950170-25-009227.json
- Plain text: https://secwatch.observer/filing/0000950170-25-009227.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.